Display options
Cite
Guo T, Chamoto K, Hirano N. Adoptive T Cell Therapy Targeting CD1 and MR1. Front Immunol. 2015;6:247doi: 10.3389/fimmu.2015.00247.
Guo, T., Chamoto, K., & Hirano, N. (2015). Adoptive T Cell Therapy Targeting CD1 and MR1. Frontiers in immunology, 6247. https://doi.org/10.3389/fimmu.2015.00247
Guo, Tingxi, et al. "Adoptive T Cell Therapy Targeting CD1 and MR1." Frontiers in immunology vol. 6 (2015): 247. doi: https://doi.org/10.3389/fimmu.2015.00247
Guo T, Chamoto K, Hirano N. Adoptive T Cell Therapy Targeting CD1 and MR1. Front Immunol. 2015 May 20;6:247. doi: 10.3389/fimmu.2015.00247. eCollection 2015. PMID: 26052329; PMCID: PMC4440381.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2015 May 20;6:247. doi: 10.3389/fimmu.2015.00247. eCollection 2015.

Adoptive T Cell Therapy Targeting CD1 and MR1.

Frontiers in immunology

Tingxi Guo, Kenji Chamoto, Naoto Hirano

Affiliations

  1. Department of Immunology, University of Toronto , Toronto, ON , Canada ; Princess Margaret Cancer Centre, University Health Network , Toronto, ON , Canada.
  2. Princess Margaret Cancer Centre, University Health Network , Toronto, ON , Canada.

PMID: 26052329 PMCID: PMC4440381 DOI: 10.3389/fimmu.2015.00247

Abstract

Adoptive T cell immunotherapy has demonstrated clinically relevant efficacy in treating malignant and infectious diseases. However, much of these therapies have been focused on enhancing, or generating de novo, effector functions of conventional T cells recognizing HLA molecules. Given the heterogeneity of HLA alleles, mismatched patients are ineligible for current HLA-restricted adoptive T cell therapies. CD1 and MR1 are class I-like monomorphic molecules and their restricted T cells possess unique T cell receptor specificity against entirely different classes of antigens. CD1 and MR1 molecules present lipid and vitamin B metabolite antigens, respectively, and offer a new front of targets for T cell therapies. This review will cover the recent progress in the basic research of CD1, MR1, and their restricted T cells that possess translational potential.

Keywords: CD1; MAIT; MR1; NKT; T cell; adoptive cell transfer; immunotherapy

References

  1. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86 - PubMed
  2. Nat Immunol. 2015 Mar;16(3):258-66 - PubMed
  3. J Cell Physiol. 2013 Feb;228(2):457-68 - PubMed
  4. J Exp Med. 2014 Jul 28;211(8):1601-10 - PubMed
  5. Nat Immunol. 2012 Sep;13(9):857-63 - PubMed
  6. J Exp Med. 2013 Oct 21;210(11):2305-20 - PubMed
  7. PLoS Biol. 2010 Jun 22;8(6):e1000402 - PubMed
  8. Nat Immunol. 2011 Jul 31;12(9):827-33 - PubMed
  9. Nat Immunol. 2010 Dec;11(12):1102-9 - PubMed
  10. J Exp Med. 2014 Jul 28;211(8):1585-600 - PubMed
  11. Nat Commun. 2014 May 15;5:3866 - PubMed
  12. Blood. 2014 Oct 30;124(18):2824-33 - PubMed
  13. J Clin Invest. 2007 May;117(5):1137-46 - PubMed
  14. Nature. 1994 Dec 15;372(6507):691-4 - PubMed
  15. Immunity. 2011 Mar 25;34(3):315-26 - PubMed
  16. Clin Cancer Res. 2005 Mar 1;11(5):1910-7 - PubMed
  17. PLoS One. 2009;4(5):e5325 - PubMed
  18. Blood. 2013 Jan 17;121(3):423-30 - PubMed
  19. Clin Cancer Res. 2002 Dec;8(12):3702-9 - PubMed
  20. J Immunol. 1998 Oct 15;161(8):4066-77 - PubMed
  21. Nat Immunol. 2012 Sep;13(9):851-6 - PubMed
  22. Int Immunol. 2010 Nov;22(11):863-73 - PubMed
  23. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1827-32 - PubMed
  24. PLoS Biol. 2009 Oct;7(10):e1000228 - PubMed
  25. Nature. 2012 Nov 29;491(7426):717-23 - PubMed
  26. Nat Immunol. 2011 Jun 12;12(7):616-23 - PubMed
  27. Infect Immun. 2008 Jul;76(7):3011-8 - PubMed
  28. Nat Immunol. 2012 Mar 18;13(5):474-80 - PubMed
  29. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13433-8 - PubMed
  30. Leukemia. 2005 Apr;19(4):551-6 - PubMed
  31. J Immunol. 2011 Apr 15;186(8):4744-50 - PubMed
  32. Sci Transl Med. 2011 Apr 27;3(80):80ra34 - PubMed
  33. Clin Cancer Res. 2011 Aug 15;17(16):5392-401 - PubMed
  34. J Immunol. 1991 Oct 15;147(8):2518-24 - PubMed
  35. Proc Natl Acad Sci U S A. 2013 May 7;110(19):E1771-8 - PubMed
  36. Nature. 2000 Apr 20;404(6780):884-8 - PubMed
  37. Nat Rev Microbiol. 2007 Jun;5(6):405-17 - PubMed
  38. Eur J Immunol. 2012 Sep;42(9):2505-10 - PubMed
  39. EMBO J. 2012 Apr 18;31(8):2047-59 - PubMed
  40. J Exp Med. 2014 Jun 30;211(7):1363-77 - PubMed
  41. Science. 2004 Jan 23;303(5657):527-31 - PubMed
  42. J Hepatol. 2007 Sep;47(3):356-65 - PubMed
  43. J Clin Invest. 2005 Sep;115(9):2572-83 - PubMed
  44. J Exp Med. 2013 Apr 8;210(4):729-41 - PubMed
  45. J Virol. 2011 Aug;85(16):8093-104 - PubMed
  46. Clin Cancer Res. 2007 Mar 15;13(6):1857-67 - PubMed
  47. Nat Rev Immunol. 2012 Mar 22;12(4):269-81 - PubMed
  48. J Immunol. 2002 Jun 1;168(11):5514-20 - PubMed
  49. Immunol Lett. 2005 Apr 15;98(1):131-5 - PubMed
  50. Clin Immunol. 2013 Oct;149(1):55-64 - PubMed
  51. J Clin Invest. 2011 Jun;121(6):2493-503 - PubMed
  52. Eur J Immunol. 2011 Mar;41(3):694-705 - PubMed
  53. J Clin Invest. 2009 Jun;119(6):1524-36 - PubMed
  54. Clin Immunol. 2011 Mar;138(3):255-65 - PubMed
  55. J Exp Med. 2000 Mar 20;191(6):937-48 - PubMed
  56. Curr Opin Immunol. 2014 Feb;26:7-13 - PubMed
  57. Nature. 2007 Jul 5;448(7149):44-9 - PubMed
  58. Science. 2004 Dec 3;306(5702):1786-9 - PubMed
  59. J Clin Pathol. 2015 Mar;68(3):200-5 - PubMed
  60. Nat Immunol. 2014 Feb;15(2):177-85 - PubMed
  61. Annu Rev Immunol. 2014;32:323-66 - PubMed
  62. Nat Med. 2012 Jul;18(7):1060-8 - PubMed
  63. J Immunol. 2009 Feb 15;182(4):2492-501 - PubMed
  64. Nature. 2014 May 15;509(7500):361-5 - PubMed
  65. Annu Rev Immunol. 2014;32:189-225 - PubMed
  66. Curr Opin Immunol. 2014 Feb;26:1-6 - PubMed
  67. J Exp Med. 1998 Oct 19;188(8):1521-8 - PubMed
  68. Nat Immunol. 2013 Jul;14(7):706-13 - PubMed
  69. J Invest Dermatol. 2003 Sep;121(3):517-21 - PubMed
  70. Immunol Rev. 2014 Jan;257(1):191-209 - PubMed
  71. Leukemia. 2003 Jun;17(6):1068-77 - PubMed
  72. Anal Chem. 2012 Nov 6;84(21):8917-26 - PubMed
  73. Science. 1997 Oct 10;278(5336):283-6 - PubMed
  74. Immunity. 2014 Oct 16;41(4):543-54 - PubMed
  75. Curr Top Microbiol Immunol. 2007;314:113-41 - PubMed
  76. Immunology. 1993 Dec;80(4):561-5 - PubMed
  77. Antivir Ther. 2009;14(6):809-18 - PubMed
  78. J Immunol. 2013 Jul 1;191(1):30-4 - PubMed
  79. Nat Immunol. 2013 Nov;14(11):1146-54 - PubMed
  80. J Clin Invest. 2014 Sep;124(9):3725-40 - PubMed
  81. Blood. 2015 Feb 19;125(8):1256-71 - PubMed
  82. Nat Immunol. 2011 Oct 30;12(12):1202-11 - PubMed
  83. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):E4648-57 - PubMed
  84. Nat Commun. 2014;5:3143 - PubMed
  85. Eur J Immunol. 2011 Mar;41(3):602-10 - PubMed
  86. Blood. 2011 Jan 27;117(4):1250-9 - PubMed
  87. Blood. 2009 Mar 12;113(11):2498-507 - PubMed
  88. Nat Commun. 2013;4:2142 - PubMed
  89. Eur J Immunol. 2005 Jun;35(6):1692-701 - PubMed
  90. Nat Immunol. 2013 Nov;14(11):1137-45 - PubMed
  91. Curr Opin Immunol. 2008 Jun;20(3):358-68 - PubMed
  92. Cancer Sci. 2009 Jun;100(6):1092-8 - PubMed
  93. Blood. 2009 Jul 16;114(3):535-46 - PubMed
  94. Immunol Rev. 2014 Jan;257(1):264-76 - PubMed
  95. Nature. 2003 Mar 13;422(6928):164-9 - PubMed
  96. Immunol Rev. 2014 Jan;257(1):56-71 - PubMed
  97. Nat Immunol. 2011 Sep 04;12(10):966-74 - PubMed
  98. Cancer Immunol Immunother. 2008 Mar;57(3):337-45 - PubMed
  99. Nature. 2003 Oct 23;425(6960):805-11 - PubMed

Publication Types

Grant support